Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
about
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockadeQualitative Neuromuscular Monitoring: How to Optimize the Use of a Peripheral Nerve Stimulator to Reduce the Risk of Residual Neuromuscular BlockadeDiscovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery?Respiratory complications in the postanesthesia care unit: A review of pathophysiological mechanisms.Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients.Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort studySugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center.A Comparision of the Effect of Sugammadex on the Recovery Period and Postoperative Residual Block in Young Elderly and Middle-Aged Elderly Patients.Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.Sugammadex in anesthesia practice.Neuromuscular blocking agents for electroconvulsive therapy: a systematic review.Development of an algorithm using clinical tests to avoid post-operative residual neuromuscular block.Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.Postoperative residual block in postanesthesia care unit more than two hours after the administration of a single intubating dose of atracurium.Postoperative awake paralysis in the intensive care unit after cardiac surgery due to residual neuromuscular blockade: a case report and prospective observational study.Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex.Preparing for the unexpected: special considerations and complications after sugammadex administrationPostoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used.Neuromuscular blockade improves surgical conditions (NISCO).Dose-reversal effect relationship of three different doses of neostigmine in obese patients: A randomised clinical trial.Not just monitoring; a strategy for managing neuromuscular blockade.Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.The effect of neuromuscular blockade on canine laparoscopic ovariectomy: a double-blinded, prospective clinical trial.Retrospective analysis of spontaneous recovery from neuromuscular blockade produced by empirical use of rocuronium.Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium.Clinically suspected anaphylaxis induced by sugammadex in a patient with Weaver syndrome undergoing restrictive mammoplasty surgery: A case report with the literature review.Reversal agents: do we need to administer with neuromuscular monitoring - an observational study.Neuromuscular Block and Blocking Agents in 2018.
P2860
Q24240695-4D72876A-8B3A-4097-98BF-F80771137E2BQ26741519-9843D9C4-FCAA-4D80-8B33-084B3F16DDE4Q34613962-1FC10E41-CE6F-426C-B5F8-0888EFA480EEQ34711497-DE5014E4-5986-4270-A882-E65DB672BC3BQ35686668-29C41632-F845-464C-8334-D7DC95D8ADC5Q35774826-33A51749-B7E8-430E-AC3D-118C9B131232Q36322710-6C5BDF42-5C1D-4E0B-AAAE-2BD6B5A573CDQ36603957-A8F4331F-6CA1-4DEB-B74E-253B4663915EQ37047166-A2B9E1B9-C681-4704-9B3E-D5F795845AA5Q37464166-AFDC20D8-9FE0-40D8-9A45-DAE7E0ADB53DQ37803242-9449CB7B-1716-48BB-8320-A197196DF9E5Q37957197-35C8F3B8-EFA0-439B-9295-45DD3E5288F4Q38372688-CF3E70A1-889E-4E0A-81F3-1E2DBFECC6BFQ38625776-682B2FB5-1311-4037-B874-0E565B12307BQ39050598-8A312848-694B-482F-9A57-DB8117B75F02Q40875156-34CAF8BF-AEC9-426B-8E54-9CA413128AE3Q42595866-38664827-2680-419C-BF2C-6EEA96B50BECQ42682587-5A3169BE-E0A7-461E-A56C-CD059719CF39Q43953604-9B25604E-900C-494F-8514-34F0F55849F0Q44775402-51ACBD02-A85A-4F97-AE0C-533C45909288Q47108975-34B08D0C-C308-4CC9-9C1C-FF349FE0352EQ47652970-82FB54E3-8B35-4074-8244-70D0330A4739Q47741946-F91D12AB-928C-4066-B191-CA790D100E8DQ48105917-8AE374DE-1260-4069-BAD4-9A1E82EF1113Q48229153-61F8F4FC-F791-4FCC-B12D-F7E7BBC6E775Q48638022-CBA28A97-C4EE-4A0F-A1C0-256818B4E7C1Q49246933-E5CEFF69-85A1-4188-B7E6-E5E5687E4F06Q53830812-D424D2AA-ED89-4B18-8965-53F2FA4B26FEQ55215771-19291CD1-6B9A-44DE-93DB-8B5A1D2F57A4
P2860
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@en
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@nl
type
label
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@en
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@nl
prefLabel
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@en
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@nl
P2093
P1433
P1476
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
@en
P2093
P304
P356
10.1046/J.1365-2044.2001.01921.X
P407
P577
2001-04-01T00:00:00Z